Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches

Inflammatory bowel disease (IBD) management has changed dramatically over the past 20 years, after the introduction of targeted biological therapies. However, the impact of these new drugs in changing the natural history of disease is still under debate. Recent evidence seems to suggest that the ext...

Full description

Bibliographic Details
Main Authors: Giuseppe Privitera, Daniela Pugliese, Loris Riccardo Lopetuso, Franco Scaldaferri, Matteo Neri, Luisa Guidi, Antonio Gasbarrini, Alessandro Armuzzi
Format: Article
Language:English
Published: SAGE Publishing 2021-04-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/17562848211006669
id doaj-420826fec6b048e18ce6cc197bf65888
record_format Article
spelling doaj-420826fec6b048e18ce6cc197bf658882021-04-27T22:03:45ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482021-04-011410.1177/17562848211006669Novel trends with biologics in inflammatory bowel disease: sequential and combined approachesGiuseppe PriviteraDaniela PuglieseLoris Riccardo LopetusoFranco ScaldaferriMatteo NeriLuisa GuidiAntonio GasbarriniAlessandro ArmuzziInflammatory bowel disease (IBD) management has changed dramatically over the past 20 years, after the introduction of targeted biological therapies. However, the impact of these new drugs in changing the natural history of disease is still under debate. Recent evidence seems to suggest that the extent of their efficacy might be, at least partially, dependent on the timing of their introduction and on the subsequent management strategy. In this complex landscape, the potential role for a more dynamic approach with treatments based on sequencing and combining targeted therapies has been explored only minimally so far. In this review, we aim to explore the potential biological rationale behind the use of sequential and combination therapies in IBD, to summarise the current knowledge on this topic and to propose a management algorithm that combines these notions.https://doi.org/10.1177/17562848211006669
collection DOAJ
language English
format Article
sources DOAJ
author Giuseppe Privitera
Daniela Pugliese
Loris Riccardo Lopetuso
Franco Scaldaferri
Matteo Neri
Luisa Guidi
Antonio Gasbarrini
Alessandro Armuzzi
spellingShingle Giuseppe Privitera
Daniela Pugliese
Loris Riccardo Lopetuso
Franco Scaldaferri
Matteo Neri
Luisa Guidi
Antonio Gasbarrini
Alessandro Armuzzi
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
Therapeutic Advances in Gastroenterology
author_facet Giuseppe Privitera
Daniela Pugliese
Loris Riccardo Lopetuso
Franco Scaldaferri
Matteo Neri
Luisa Guidi
Antonio Gasbarrini
Alessandro Armuzzi
author_sort Giuseppe Privitera
title Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
title_short Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
title_full Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
title_fullStr Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
title_full_unstemmed Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
title_sort novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
publisher SAGE Publishing
series Therapeutic Advances in Gastroenterology
issn 1756-2848
publishDate 2021-04-01
description Inflammatory bowel disease (IBD) management has changed dramatically over the past 20 years, after the introduction of targeted biological therapies. However, the impact of these new drugs in changing the natural history of disease is still under debate. Recent evidence seems to suggest that the extent of their efficacy might be, at least partially, dependent on the timing of their introduction and on the subsequent management strategy. In this complex landscape, the potential role for a more dynamic approach with treatments based on sequencing and combining targeted therapies has been explored only minimally so far. In this review, we aim to explore the potential biological rationale behind the use of sequential and combination therapies in IBD, to summarise the current knowledge on this topic and to propose a management algorithm that combines these notions.
url https://doi.org/10.1177/17562848211006669
work_keys_str_mv AT giuseppeprivitera noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches
AT danielapugliese noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches
AT lorisriccardolopetuso noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches
AT francoscaldaferri noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches
AT matteoneri noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches
AT luisaguidi noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches
AT antoniogasbarrini noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches
AT alessandroarmuzzi noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches
_version_ 1721505546300817408